Within our cohort, AML of favourable-risk group only contain CBF AML with t(8;21);RUNX1-RUNX1T1 or inv(16);CBFB-MYH11 cytogenetics, since APL were not included. This evidence concerns the gene CEBPZ and acute myeloid leukemia.